(Nofazinlimab)Biosimilar Reference Antibody-GS40479 新品

货号：GS40479

Nofazinlimab (also known as CS‑1003) is an investigational, fully human monoclonal antibody that targets programmed cell death‑1 (PD‑1), an inhibitory immune checkpoint receptor. By binding to PD‑1 on T cells, it blocks the interaction between PD‑1 and its ligands PD‑L1 and PD‑L2, thereby reversing T‑cell exhaustion and restoring anti‑tumor immune responses. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors, with clinical trials focusing on hepatocellular carcinoma (HCC), non‑small cell lung cancer (NSCLC), and gastric cancer, both as monotherapy and in combination with other agents (e.g., anti‑VEGF therapy, chemotherapy).